Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Flibanserin som farmakologisk behandling af nedsat lyst hos kvinder
Engelsk titel: Flibanserin as pharmacological therapy of inhibited sexual desire in women Läs online Författare: Eldon, Anne Sofie ; Giraldi, Annamaria Språk: Dan Antal referenser: 30 Dokumenttyp: Översikt UI-nummer: 17060089

Tidskrift

Ugeskrift for Laeger 2017;179(11)962-6 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD.